Managing Discovery in the Life Sciences

Preface; 1. Discoveries now and then: shifting incentives and expectations Mark V. Pauly, Philip A. Rea and Lawton R. Burns; 2. Pharma trends: not what they seem Kyle Myers and Mark V. Pauly; 3. Profit maximizing drug firms: models and myths Vicki Chen and Mark V. Pauly; Transitional note: introduction to the case studies; 4. The Statins: cholesterols 'penicillins' Philip A. Rea; 5. ACE inhibitors: kidney clamps, snake venoms and peptidomimetics Alec Ren and Philip A. Rea; 6. Angioplasty: catheters, guidewires and balloons Simon Basseyn, Sourav Bose, Lawton R. Burns and Chris Groskaufmanis; 7. Hepatitis C: when cures and prices go viral Stephen Goldstein, Peter M. Stokes, Connie Lu and Philip A. Rea; 8. Alzheimer's: America's new most feared disease Julian Pei, John Q. Trojanowski, Peter M. Stokes, Katherine Clark, Mark V. Pauly and Philip A. Rea; 9. Metformin: to the brink and back Anderson Y. Tien and Philip A Rea; 10. Medical genomics: personalized precision Mark S. Williams; 11. Gleevec: from broken chromosomes to precision cancer therapy Vivek Nimgaonkar and Philip A. Rea; 12. Regeneron: agility, resilience and balance Lawton R. Burns, Alex Rosen, Steven Nichtberger and Philip A. Rea; 13. Avastin and Lucentis: both for eyesight in hindsight Osama Ahmed, Mark V. Pauly, Peter M. Stokes and Philip A. Rea; 14. CAR T-cell therapy: cures for ALL and more? Stephen Goldstein, Amy Le and Philip A. Rea; 15. Organizing discovery: wild ducks nested in multilevel ecosystems Lawton R. Burns and Philip A. Rea; 16. Can government help with the creatively unexpected? Mark V. Pauly, Lawton R. Burns and Philip A. Rea; Appendix: three key elements in the discovery process: historical and philosophical antecedents Mark V. Pauly; Index.